Thursday, December 6, 2018
LabCorp price target lowered to $165 from $210 at KeyBanc
KeyBanc analyst Donald Hooker lowered his price target for LabCorp to $165 from $210, while reiterating an Overweight rating on the shares. The analyst recommends LabCorp on relative valuation given the strength of its Covance Drug Development segment. However, the situation has deteriorated for its legacy lab business, he contended.
https://thefly.com/landingPageNews.php?id=2832939
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.